Search Page

1

Cite

Share

Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.

Colombo D, Pnevmatikou P, Melloni E, Keywood C. Colombo D, et al. Among authors: keywood c. Expert Rev Neurother. 2020 Oct;20(10):1047-1064. doi: 10.1080/14737175.2020.1800454. Epub 2020 Aug 6. Expert Rev Neurother. 2020. PMID: 32758042 Review.

Cite

Share

2

Cite

Share

Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.

Sciaccaluga M, Mazzocchetti P, Bastioli G, Ghiglieri V, Cardinale A, Mosci P, Caccia C, Keywood C, Melloni E, Padoani G, Vailati S, Picconi B, Calabresi P, Tozzi A. Sciaccaluga M, et al. Among authors: keywood c. Neuropharmacology. 2020 Jun 15;170:108024. doi: 10.1016/j.neuropharm.2020.108024. Epub 2020 Mar 3. Neuropharmacology. 2020. PMID: 32142791

Cite

Share

3

Cite

Share

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.

Pisanò CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, Vailati S, Padoani G, Morari M. Pisanò CA, et al. Among authors: keywood c. Neuropharmacology. 2020 May 1;167:108006. doi: 10.1016/j.neuropharm.2020.108006. Epub 2020 Feb 10. Neuropharmacology. 2020. PMID: 32086070

Cite

Share

4

Cite

Share

Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.

Géraud G, Keywood C, Senard JM. Géraud G, et al. Among authors: keywood c. Headache. 2003 Apr;43(4):376-88. doi: 10.1046/j.1526-4610.2003.03073.x. Headache. 2003. PMID: 12656709 Review.

Cite

Share

5

Cite

Share

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C. Cattaneo C, et al. Among authors: keywood c. J Parkinsons Dis. 2017;7(4):629-634. doi: 10.3233/JPD-171143. J Parkinsons Dis. 2017. PMID: 28777756 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisanò CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C. Gardoni F, et al. Among authors: keywood c. J Pharmacol Exp Ther. 2018 Dec;367(3):442-451. doi: 10.1124/jpet.118.251645. Epub 2018 Oct 5. J Pharmacol Exp Ther. 2018. PMID: 30291173

Cite

Share

7

Cite

Share

Metabotropic glutamate receptor 5: a target for migraine therapy.

Waung MW, Akerman S, Wakefield M, Keywood C, Goadsby PJ. Waung MW, et al. Among authors: keywood c. Ann Clin Transl Neurol. 2016 Jul 1;3(8):560-71. doi: 10.1002/acn3.302. eCollection 2016 Aug. Ann Clin Transl Neurol. 2016. PMID: 27606340 Free PMC article.

Cite

Share

8

Cite

Share

Clinical pharmacokinetics of frovatriptan.

Buchan P, Keywood C, Wade A, Ward C. Buchan P, et al. Among authors: keywood c. Headache. 2002 Apr;42 Suppl 2:S54-62. doi: 10.1046/j.1526-4610.42.s2.3.x. Headache. 2002. PMID: 12028321 Clinical Trial.

Cite

Share

9

Cite

Share

Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo.

Desaphy JF, Farinato A, Altamura C, De Bellis M, Imbrici P, Tarantino N, Caccia C, Melloni E, Padoani G, Vailati S, Keywood C, Carratù MR, De Luca A, Conte D, Pierno S. Desaphy JF, et al. Among authors: keywood c. Exp Neurol. 2020 Jun;328:113287. doi: 10.1016/j.expneurol.2020.113287. Epub 2020 Mar 20. Exp Neurol. 2020. PMID: 32205118

Cite

Share

10

Cite

Share

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H. Svenningsson P, et al. Among authors: keywood c. Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10. Brain. 2015. PMID: 25669730 Free PMC article. Clinical Trial.

Cite

Share